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OBJECTIVES: The objective of this study was to cross-culturally adapt and validate 
the Incontinence-Speciﬁ c Quality of Life instrument (I-QOL) for Brazilian women with 
urinary incontinence. METHODS: The I-QOL is a scale devised to assess quality of 
life impairment due to urinary incontinence. This questionnaire has been used in 
numerous studies to evaluate the consequences of the disease in daily life or the effects
of different treatments. Seventy patients with urinary incontinence, were enrolled from
the outpatient clinic of the Uroginecology and Vaginal Surgery Section of the Gynecol-
ogy Department of the Federal University of São Paulo (UNIFESP). Initially, we 
translated the I-QOL into Brazilian Portuguese language following international meth-
odological recommendations. Due to language and cultural differences we performed
cultural, structural, conceptual, and semantic adaptation on the I-QOL, in order that
patients were able to fully understand the questions. All patients answered I-QOL 
twice on the same day with an interval of 30 minutes, applied by two different inter-
viewers. Also the Kingxs Health Questionnaire (KHQ), already translated and vali-
dated to Brazilian Portuguese was applied to the patients. After 7 to 15 days, by phone
interview, only I-QOL was applied again. Reliability (intra and inter observer internal
consistency), construct and discriminative validity were tested. RESULTS: Several
cultural adaptations were necessary until we reached the ﬁ nal version. The intra-
observer internal consistence (alpha of Cronbachxs) of the several dimensions varied
from moderate to high (0.77–0.93), and the inter observer internal consistence varied
from 0.65 to 0.88. Moderate to strong correlation was detected among the I-QOL
dominions and the validated Brazilian Portuguese version of KHQ. CONCLUSIONS:
I-QOL was adapted to the Portuguese language and to the Brazilian culture, showing
good reliability and validity. This questionnaire is now being evaluated in clinical trials
on new therapeutic strategies for urinary incontinence in Brazil.
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OBJECTIVES: The FDA draft guidance on patient-reported outcomes (PROs) outlines
methods for developing disease-speciﬁ c PROs. The aim of the present study was to
develop and validate vignette descriptions of health-related quality of life (HRQL) in 
people who have anemia associated with chronic kidney disease (CKD) by adapting 
the FDA methods for developing PROs to derive health state utilities. METHODS:
Interviews with people with CKD (n  12) provided detailed qualitative data regarding
patients’ HRQL. Qualitative analysis identiﬁ ed how HRQL varied by three levels of 
anemia (mild  12.5 g/dL; moderate 12.5–10.5 g/dL, and severe  10.5 g/dL; set
according to the recent National Institute of Clinical Excellence [NICE] clinical guide-
lines on CKD) and three states of CKD (pre-dialysis, peritoneal dialysis, and hemodi-
alysis). Vignette descriptions of HRQL were developed for each state, and patients 
and clinicians assessed content validity. Vignettes were rated by 100 members of the
general public in the UK using the time trade-off interview to estimate health state 
utilities. RESULTS: The qualitative data produced very detailed vignettes that were 
determined by patients and clinicians to have good content validity. Utilities varied 
for pre-dialysis (0.787–0.431), peritoneal dialysis (0.725–0.351), and hemodialysis
(0.629–0.331) between mild to severe levels of anemia, respectively. CONCLUSIONS:
The vignette descriptions were based upon qualitative data and validated through
content validation interviews with clinicians and patients. To our knowledge, this is
the ﬁ rst study in which vignettes have been developed entirely based on qualitative
data from patient interviews. This is a useful method for estimating utilities when no 
data from generic instruments are available.
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OBJECTIVES: Tamsulosin Ocas (oral controlled absorption system) is an improved
formulation of tamsulosin modiﬁ ed release (MR) capsules, providing a smoother 24h
plasma concentration proﬁ le, improved Cmax/C24h ratio, and independence from
oral food intake [1]. The formulations are similarly effective, but tamsulosin Ocas is 
associated with a lower incidence of orthostatic hypotension and abnormal ejaculation 
[2,3]. Our objective was to determine if patients preferred tamsulosin Ocas over tam-
sulosin MR. METHODS: Discrete Choice Analysis based on 12 hypothetical paired
scenarios was used to compare patient preferences in 50 men aged q45 years with
LUTS/BPH. Each scenario included convenience of administration with/without food, 
frequency of orthostatic hypotension, ejaculatory dysfunction, and out-of-pocket
expenses; one mandatory pair tested for irrationality. Disease severity and health-
related quality of life were assessed by IPSS and EuroQol EQ-5D. RESULTS: 56% of 
the trial population had moderate and 26% had severe symptoms on IPSS scores;
mean EQ-5D was 0.78. Five respondents with irrational responses were excluded.
Respondents were signiﬁ cantly more likely to prefer tamsulosin Ocas over MR overall 
(OR 19.45; 95% CI 6.27, 60.39; p  0.001). Orthostatic hypotension was the most
important factor driving this preference (OR 9.07; 95% CI 4.61, 17.82; p  0.001). 
On average, participants would have been willing to pay an extra 72.00GBP per 
month (range 32.40–144.40) for tamsulosin Ocas over MR; orthostatic hypotension 
contributed 76% to the choice for overall WTP. CONCLUSIONS: There was a strong 
patient preference for tamsulosin Ocas over tamsulosin MR that was primarily driven
by the orthostatic hypotension attribute. This preference equated to patients being 
willing to pay about 72GBP more per month for tamsulosin OCAS; the actual cost 
differential between the two formulations is 11.27GBP. REFERENCES: [1] Chapple
CR, Chartier-Kastler E. BJU Int 2006;29Suppl.):S9–12.; [2] Chapple CR, et al. Eur 
Urol 2005;4(Suppl.):S33–44; [3] Michel MC, et al. Eur Urol 2005;4(Supp.):S53–60.
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OBJECTIVES: To assess the efﬁ cacy of solifenacin on patient-reported outcomes and
diary-documented Overactive Bladder (OAB) symptoms. METHODS: 768 patients 
with OAB for q3 months were randomized to ﬂ exibly dosed solifenacin (5–10 mg) or 
placebo for 12 weeks; dose modiﬁ cations were permitted at Weeks 4 and 8. At baseline 
and Week 12, patients completed the Overactive Bladder Questionnaire (OAB-q),
comprised of a Symptom Bother scale (primary endpoint) and Health-Related Quality 
of Life (HRQL) scale with 4 domains (Coping, Concern, Sleep, Social Interactions),
Work Productivity and Activity Impairment (WPAI) Questionnaire, which assesses the 
impact of bladder-related problems on absenteeism (work time missed), presenteeism
(impairment at work), work productivity loss, and activity impairment, a 100-mm
Treatment Satisfaction Visual Analog Scale (TS-VAS; higher values indicate greater 
satisfaction) and 3-day bladder diaries for recording episodes of urgency, incontinence,
micturition frequency, and nocturia. RESULTS: By study end, solifenacin versus 
placebo signiﬁ cantly improved mean OAB-q Symptom Bother (29.9 vs 20.4, P 
0.0001), HRQL total (25.3 vs 16.7, P  0.0001) and all domain scores (all Ps 
0.0001). WPAI results revealed that solifenacin versus placebo signiﬁ cantly improved 
presenteeism (14.6% vs 8.7%), work productivity loss (12.9% vs 8.2%), and 
activity impairment (18.1% vs 14.7%; all Ps  0.01), but not absenteeism (0.5 vs 
0.1; P  0.50), likely because baseline levels were low (1.1% vs. 1.4%). On the TS-
VAS, mean change from baseline was signiﬁ cantly larger among solifenacin versus
placebo patients (38.2 vs 18.4; P  0.0001). Solifenacin vs placebo also signiﬁ cantly 
reduced mean daily episodes of urgency (3.05 vs 1.84; P  0.0001), incontinence
(1.85 vs 1.24; P  0.003), and frequency (2.23 vs 1.36; P  0.0001), but not 
nocturia (0.63 vs 0.48; P  0.34). CONCLUSIONS: Flexibly dosed solifenacin sig-
niﬁ cantly improved OAB symptom bother, HRQL, work productivity, and OAB 
symptoms. Patients who received solifenacin versus placebo also showed a signiﬁ cantly 
greater increase in overall treatment satisfaction.
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OBJECTIVES: Patients with chronic kidney disease (CKD) often have ﬁ ve to six other
co-morbid conditions thus requiring extensive therapeutic treatment. Therefore, the
objective of this study was to examine the most common co-morbid conditions and
medications prescribed among patients with CKD, using a recent national population 
based ambulatory care survey. METHODS: This study utilized the National Ambula-
tory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical 
Care Survey (NHAMCS) data from 2002 through 2005. The NAMCS and NHAMCS
are national probability surveys of visits to ofﬁ ce-based physicians and ambulatory
services in hospital outpatient and emergency departments. CKD-related visits were 
identiﬁ ed using diagnosis codes (ICD-9-CM: 016.0, 572.4, 580–588, 591, 593.9,
572.4, 753.1, 753.3, 753.2, V18.6,794.4) or prescription for CKD speciﬁ c medica-
tions (brand and generic drug codes: calcium acetate,sevelamer,lanthanum car-
bonate,cinacalcet). Frequency analysis of the CKD visits by setting and demographic
characteristics was performed. Similarly, frequency analysis was performed to identify
the most common co-morbid diagnosis and medications prescribed among CKD 
patients. National estimates on visits were estimated using patient visits weights pro-
vided in the NAMCS and NHAMCS. RESULTS: In, 2005 there were 9.7million visits
related to CKD, 8.1 million physician ofﬁ ce visits, 0.9 million emergency department,
and 0.7 million outpatient hospital department visits, representing a 140% increase 
compared to 7.1 million visits in 2002. The most common co-morbid conditions
among CKD patients were essential hypertension (22.3%), diabetes mellitus (17.5%),
